Previous close | 17.08 |
Open | 17.44 |
Bid | 16.99 x 200 |
Ask | 17.05 x 600 |
Day's range | 17.03 - 17.58 |
52-week range | 16.16 - 33.99 |
Volume | |
Avg. volume | 1,809,683 |
Market cap | 2.817B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.37 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 28.96 |
On May 2, 2024, Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), sold 11,427 shares of the company.
SAN DIEGO, April 29, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year.
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...